Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $14.55
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $14.55
Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) shares gapped down prior to trading on Friday . The stock had previously closed at $14.55, but opened at $13.89. Repare Therapeutics shares last traded at $13.93, with a volume of 400 shares.
Repare治疗公司(纳斯达克代码：RPTX-GET评级)的股价在周五交易前大幅下跌。该股此前收盘报14.55美元，开盘报13.89美元。Repare Treateutics的股票尾盘报13.93美元，成交量为400股。
Analyst Ratings Changes
分析师评级发生变化
A number of analysts have recently issued reports on the stock. Capital One Financial initiated coverage on shares of Repare Therapeutics in a report on Friday. They set an "overweight" rating and a $28.00 price target for the company. HC Wainwright dropped their price target on shares of Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, November 17th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $30.80.
一些分析师最近发布了关于该股的报告。Capital One Financial在周五的一份报告中启动了对Repare治疗公司股票的覆盖。他们为该公司设定了“增持”评级和28.00美元的目标价。11月17日星期四，HC Wainwright在一份研究报告中将Repare Treateutics的股票目标价从38.00美元下调至25.00美元，并为该公司设定了“买入”评级。一名分析师对该股的评级为持有，五名分析师对该公司的评级为买入。根据MarketBeat的数据，该公司的普遍评级为“适度买入”，平均目标价为30.80美元。
Repare Therapeutics Price Performance
修复治疗药物的价格表现
The firm's 50-day simple moving average is $15.56 and its two-hundred day simple moving average is $13.94. The company has a market capitalization of $615.55 million, a price-to-earnings ratio of -19.93 and a beta of 0.11.
该公司50日简单移动均线切入位为15.56美元，200日简单移动均线切入位为13.94美元。该公司市值为6.1555亿美元，市盈率为-19.93倍，贝塔系数为0.11。
Insider Activity at Repare Therapeutics
Repare治疗公司的内部活动
In related news, Director Davis Jerel sold 250,000 shares of the company's stock in a transaction that occurred on Friday, December 9th. The shares were sold at an average price of $16.00, for a total transaction of $4,000,000.00. Following the transaction, the director now owns 2,094,451 shares of the company's stock, valued at $33,511,216. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 33.60% of the company's stock.
在相关新闻中，董事戴维斯·杰里尔在12月9日(星期五)的一笔交易中出售了250,000股该公司股票。这些股票的平均价格为16.00美元，总成交金额为4,000,000.00美元。交易完成后，董事现在持有该公司2,094,451股股票，价值33,511,216美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过这个环节。内部人士持有该公司33.60%的股份。
Hedge Funds Weigh In On Repare Therapeutics
对冲基金参与Repare Treeutics
A number of large investors have recently bought and sold shares of the stock. Deep Track Capital LP raised its stake in Repare Therapeutics by 26.9% during the first quarter. Deep Track Capital LP now owns 2,664,017 shares of the company's stock worth $37,936,000 after purchasing an additional 564,017 shares during the period. Affinity Asset Advisors LLC increased its position in shares of Repare Therapeutics by 72.5% in the first quarter. Affinity Asset Advisors LLC now owns 468,905 shares of the company's stock worth $6,677,000 after acquiring an additional 197,127 shares in the last quarter. BlackRock Inc. increased its position in shares of Repare Therapeutics by 1.9% in the first quarter. BlackRock Inc. now owns 467,311 shares of the company's stock worth $6,655,000 after acquiring an additional 8,680 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Repare Therapeutics in the third quarter worth $2,269,000. Finally, Renaissance Technologies LLC increased its position in shares of Repare Therapeutics by 105.3% in the second quarter. Renaissance Technologies LLC now owns 180,900 shares of the company's stock worth $2,531,000 after acquiring an additional 92,800 shares in the last quarter. Hedge funds and other institutional investors own 78.19% of the company's stock.
一些大型投资者最近买卖了该股的股票。第一季度，Deep Track Capital LP将其在Repare Treateutics的持股增加了26.9%。在此期间，Deep Track Capital LP额外购买了564,017股，目前拥有2,664,017股该公司股票，价值37,936,000美元。Affiliation Asset Advisors LLC在第一季度将其在Repare Treeutics股票的持仓增加了72.5%。Affiliation Asset Advisors LLC在上个季度增持了197,127股后，现在拥有468,905股该公司股票，价值6,677,000美元。贝莱德股份有限公司在第一季度增持了Repare治疗公司的股票1.9%。贝莱德股份有限公司在上个季度增持了8,680股后，目前持有467,311股该公司股票，价值6,655,000美元。三井住友信托控股公司在第三季度收购了价值226.9万美元的Repare治疗公司的新股份。最后，复兴科技有限责任公司在第二季度将其在Repare治疗公司的股票持有量增加了105.3%。复兴科技有限责任公司在上个季度增持了92,800股后，现在拥有180,900股该公司股票，价值2,531,000美元。对冲基金和其他机构投资者持有该公司78.19%的股份。
About Repare Therapeutics
关于Repare Treeutics
(Get Rating)
(获取评级)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Repare治疗公司是一家临床阶段的精确肿瘤学公司，通过在加拿大和美国使用其合成致命性方法来发现和开发治疗方法。该公司使用其SNIPRx，这是一个专有的、全基因组的和支持CRISPR的平台，以系统地发现和开发专注于基因组不稳定性(包括DNA损伤修复)的高度针对性的癌症疗法。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
- Is Your Portfolio Flexible Enough for FLEX Stock?
- How 2022's Biggest Healthcare Gainers Could Fare In 2023
- 免费获取StockNews.com关于Repare治疗的研究报告(RPTX)
- 2023年四只被低估的医疗保健股票
- WWE股票：文斯·麦克马洪想要重返节目
- NVIDIA正在触底，但现在还不能买入
- 你的投资组合对Flex股票足够灵活吗？
- 2022年最大的医疗保健获益者在2023年的表现如何
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Repare治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Repare Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。